Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
NYU's cancer centre, comprehensive since 2019, known for melanoma immunotherapy, RAS and SHP2 biology, and early deep-learning pathology.
NCI-designated since the 1970s and comprehensive since 2019, Perlmutter Cancer Center spans NYU Langone's Manhattan, Brooklyn and Long Island hospitals. Its melanoma programme (Jeffrey Weber, Iman Osman, Anna Pavlick) led adjuvant nivolumab trials; Benjamin Neel, the director, discovered the phosphatase SHP2 (PTPN11), now a drug target in RAS-driven cancers; Dafna Bar-Sagi's laboratory defined how KRAS-mutant pancreatic cancers scavenge nutrients. Aristotelis Tsirigos's 2018 study of deep learning on lung cancer histology slides was an early landmark in computational pathology. Michele Pagano's work on ubiquitin ligases underpins targeted protein degradation.
- Melanoma immunotherapy
- RAS and SHP2 biology
- Computational pathology
Pages like this
not linked directly; found by shared links- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares KRAS, The undruggable drivers, Non-small-cell lung cancer.
- TrialCodeBreaK 200
Shares KRAS, The undruggable drivers, Non-small-cell lung cancer.
- TrialKRYSTAL-12
Shares KRAS, The undruggable drivers, Non-small-cell lung cancer.
- ProductElironrasib
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Nivolumab, PD-1, Melanoma, Non-small-cell lung cancer.
- PersonTasuku Honjo
Shares Nivolumab, PD-1, Melanoma, Non-small-cell lung cancer.
- PersonSuzanne L. Topalian
Shares Nivolumab, PD-1, Melanoma, Non-small-cell lung cancer.